ImmunityBio, Inc. - Common Stock (IBRX)

A diverse group of small- and mid-cap companies across defense technology, digital assets, biotech, energy, and education are drawing increased investor focus as new developments signal potential momentum heading into the next market cycle. From U.S. Marine Corps VR deployments to $1B debt reduction moves and biotech trial validation, multiple sectors are driving renewed investor attention.

NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring Committee (IDMC) review of the interim data, the committee recommended that the study is adequately powered to detect the pre-specified clinically meaningful difference in complete response (CR) rate between the experimental arm (ANKTIVA + BCG) and the control arm (BCG alone) at the protocol-specified power, in the randomized QUILT-2.005 (NCT02138734) study. The QUILT-2.005 study was designed to detect the pre-specified difference in CR rate between ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) and BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary disease, based on its review of the planned interim analysis.

NEW YORK, NY - March 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public.

On March 24, 2026, choppy, oil-driven trading and fresh AI disruption fears pressured major U.S. indexes.

Perhaps the company's management will be more careful after a third regulatory run-in.

ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions.

The young biopharma outfit's growth potential continues to expand.

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln).

As capital rotation intensifies across micro- and small-cap equities in 2026, a new wave of sub-$10 stocks is gaining traction among investors seeking exposure to high-growth themes including immunotherapy breakthroughs, immersive XR technology, next-generation medical diagnostics, and AI-driven supply-chain security . Four companies— ImmunityBio (NASDAQ: IBRX), Virtuix (NASDAQ: VTIX), ENDRA Life Sciences (NASDAQ: NDRA), and SMX (NASDAQ: SMX) —are increasingly appearing on investor watchlists as catalysts build across multiple sectors.

The NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA for more patients. This move broadens its potential use, though the indication is still not FDA-approved.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.

Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement.

ImmunityBio also completed a Phase 1 study combining its memory cytokine-enhanced NK cell therapy with ANKTIVA.

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform.

The company expects global expansion to drive “substantial” revenue starting in 2027.

The project relies on an AI-driven manufacturing robot, Leonardo, to automate production and potentially scale NK cell output.

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva.